Combined organization brings broader predictive capabilities to drug discovery at scale RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software. The transaction is expected to close in the second half of 2024, subject to regulatory approval and other customary closing conditions. In 2024, Chemaxon is expected to gene ...

Certara, excluding Chemaxon, is reiterating 2024 revenue, adjusted EBITDA margin, and adjusted diluted earnings per share guidance consistent with the May 7th earnings call. Following transaction close, Certara will update its 2024 guidance to include contribution from Chemaxon and expects to maintain its 2024 adjusted EBITDA margin guidance of 31-33%. Media Contact: Reiterates full year 2024 guidance Forward-Looking Statements Chemaxon develops leading software products for chemical structure drawing, prop ...

A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. Investor Relations Contact: David Deuchler Gilmartin Group ir@certara.com Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its client ...

RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A liv ...

RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a "human in the loop" approach to the use of gen ...

RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a "human in the loop" approach to the use of gen ...

About Certara Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include nearly 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at www.certara.com. RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies ...

RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel. "Rona and Daniel are leaders in their fields. They have proven track records of growing teams and building high-performing businesses," said William F. Feehery Ph.D., CEO, Certara. "I'm confident they will further Certara's mission of accelerating medicines to patients through the del ...

财务数据和关键指标变化 - 第一季度总收入为9670万美元,同比增长7%,以恒定汇率计算增长6% [7][16] - 软件收入为3930万美元,同比增长19%,以恒定汇率计算增长18% [11][16] - 可计算和订阅收入占软件收入的61%,去年同期为56% [17] - 软件订单为3310万美元,同比增长8% [17][18] - 过去12个月软件订单为13950万美元,同比增长11% [18] - 第一季度软件净留存率为114% [18] - 技术服务收入为5730万美元,与去年同期持平 [13][16] - 过去12个月技术服务订单为2.56亿美元,同比下降11% [19] - 第一季度调整后EBITDA为2910万美元,调整后EBITDA利润率为30% [23] - 第一季度调整后每股收益为0.10美元 [23] 各条业务线数据和关键指标变化 - 生物模拟软件和Pinnacle 21是软件收入增长的主要驱动因素 [11] - 公司正在推进Phoenix软件从许可转向云托管,客户反馈良好 [11] - 公司正在加快开发使用AI和机器学习的监管文件编写工具CoAuthor,已获得客户广泛兴趣 [12] - 服务业务正在从2023年谨慎的客户支出中恢复 [13] - 公司去年8月进行的组织变革提高了识别和签订新交易的能力 [13] 各个市场数据和关键指标变化 - 公司尚未看到客户需求的转折点,但对2024年市场持谨慎乐观态度 [8] - 生物技术资本市场的最近强劲可能是改善的先兆,但公司保持耐心 [13] 公司战略和发展方向及行业竞争 - 公司推出Certara Cloud统一软件平台,提高软件使用便利性和数据安全性 [10] - 公司正在投资扩大商业足迹和开发新的生物模拟功能 [9][14] - 公司有信心实现2024年目标,并将继续推进战略 [14] 管理层对经营环境和未来前景的评论 - 公司对2024年前景持谨慎乐观态度,但需要一些时间才能将资金转化为订单和销售 [8] - 公司内部专注于几个关键举措,将推动下一阶段的增长 [9] - 公司相信最近生物技术资本市场的强劲可能是改善的先兆,但保持耐心 [13] 问答环节重要的提问和回答 问题1 **David Windley提问** Certara Cloud的客户采用情况如何,是否更倾向于大客户? [28][29] **William Feehery回答** Certara Cloud是公司软件产品向平台转型的一步,已有1500个客户专属门户,其中包括15家前30大制药公司。公司正在逐步向大客户推广,预计采用将会加速。 [29] 问题2 **David Windley提问** Simcyp等软件的版本更新是否会影响经济效益? [30][31] **William Feehery回答** 新版本增加功能,客户需要升级,这对公司经济效益有好处。随着向云端迁移,客户验证成本会降低,这也有利于更频繁的版本更新。 [31] 问题3 **Jeffrey Garro提问** 服务业务订单在2023年第四季度和2024年第一季度的表现如何? [37][38][39][40] **John Gallagher回答** 第一季度服务业务订单受到去年同期高基数的影响,但中小客户订单保持稳定。公司预计服务业务订单在下半年会有改善,但尚未看到转折点。 [38][39][40]

Certara, Inc. (CERT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.09, delivering a surprise of -18.18%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Certara, which belongs to t ...